iBio advances clinical pipeline after $33 million loss

• iBio reported fiscal 2026 results as it transitioned into a clinical-stage biotechnology company with IBIO-600 trials underway.
• The company reported a net loss of $33 million and ended the year with $88 million in cash and debt securities.
• iBio advanced obesity and cardiometabolic programs while expanding its pipeline through new antibody assets.

iBio (NASDAQ:IBIO) reported fiscal 2026 results as it advanced into clinical-stage development, with its Phase 1 trial of IBIO-600 progressing after 31 of 32 participants were dosed across four cohorts.

The company’s fiscal 2026 results compared with the prior year, with revenue declining to $0.1 million from $0.4 million, while research and development expenses increased to $19.6 million.

iBio reported general and administrative expenses of $10.6 million and recorded a $5 million intangible asset impairment, resulting in a fiscal 2026 net loss of $33 million, while it continued preparing multiple ascending dose escalation studies for IBIO-600.

The company stated that it plans to continue advancing its clinical and preclinical development programs.

The company advanced IBIO-610 and IBIO-800 through IND-enabling development for obesity and cardiometabolic conditions and licensed an amylin receptor antibody program from AstralBio.

Meanwhile, iBio completed financing activities including an August 2025 public offering with potential gross proceeds of up to $100 million, a $26 million private placement in January 2026, and a $100 million at-the-market facility.